Parkinson's Disease (PD)
Conditions
Keywords
Parkinson's disease (PD), BIA 9-1067, Opicapone
Brief summary
The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.
Detailed description
This was a single-centre, open-label ADME study in 6 healthy male subjects. Subjects received a single dose of 100 mg OPC, containing 3.39 MBq of \[14C\] OPC as oral capsules. The study consisted of an eligibility screening period within 3 weeks prior to drug administration, admission on Day -1, a treatment period involving drug administration on Day 1 followed by matrix collections for PK purposes and safety evaluations up to Day 11, discharge on Day 11, six 24-hour hospitalizations on Days 14/15, 21/22 (+/ 1 day), 28/29 (+/- 1 day), 42/43 (+/- 2 days), 56/57 (+/- 2 days) and 77/78 (+/ 3 days) for PK sample collections, and a follow up visit performed at least 14 days after discharge from the last 24-hour hospitalization or at early discontinuation.
Interventions
DRUGOPC
The drug substance of 100 mg OPC was administered as 1 capsule.
Sponsors
Bial - Portela C S.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Gender: male 2. Age: 18 - 55 years, inclusive 3. Body Mass Index (BMI): 18.0 - 30.0 kg/m2, inclusive Body weight (kg)and height2 (m2) 4. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, powerdrinks) and grapefruit (juice) from 48 hours prior to entry in the clinical research centre until discharge 5. Medical history without major pathology 6. Resting supine blood pressure and a resting pulse rate showing no clinically relevant deviations as judged by the MI 7. Computerised (12-lead) electrocardiogram (ECG) recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the MI 8. Willingness to use adequate contraception from the time of dosing until 3 months after the follow-up visit 9. All values for haematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the MI 10. Willingness to sign the written ICF
Exclusion criteria
1. Evidence of clinically relevant pathology 2. Mental handicap 3. History of relevant drug and/or food allergies 4. Regular/routine treatment with non-topical medications within 30 days prior to entrance into the clinical research centre 5. Smoking (less than 60 days prior to drug administration) 6. History of alcohol abuse or drug addiction (including soft drugs like cannabis products) 7. Use of concomitant medication, except for acetaminophen (paracetamol), which was allowed up to 3 days before entrance into the clinical research centre. Multivitamins and vitamin C were allowed up to 7 days before entrance into the clinical research centre. All other medication (including over the counter medication, health supplements, and herbal remedies such as St. John's wort extract) was to be stopped at least 14 days prior to entrance into the clinical research centre 8. Participation in a drug study within 60 days prior to drug administration. Participation in more than 3 other drug studies in the 10 months preceding administration of study drug 9. Donation of more than 50 mL of blood within 60 days prior to drug administration. Donation of more than 1.5 litres of blood in the 10 months preceding administration of study drug 10. Participation in another ADME study with a radiation burden -0.1 mSv in the period of 1 year before the start of the study 11. Exposure to radiation for diagnostic reasons (except dental X-rays and plain X rays of thorax and bony skeleton - excluding spinal column), during work or during participation in a medical study in the previous year 12. Irregular defecation pattern (less than once per 2 days) 13. Positive screen on drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol) 14. Intake of more than 24 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits) 15. Positive screen on hepatitis B surface antigen (HBsAg) 16. Positive screen on anti-hepatitis C virus (HCV) 17. Positive screen on anti- human immunodeficiency virus (HIV) 1/2 18. Illness within 5 days prior to drug administration
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative Recovery of [14C]-Radioactivity | pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29 | AEurine: Cumulative Recovery of \[14C\]-Radioactivity in urine AEfaeces: Cumulative Recovery of \[14C\]-Radioactivity in urine AEair: Cumulative Recovery of \[14C\]-Radioactivity in urine AEtotal: Cumulative Recovery of \[14C\]-Radioactivity in urine Recovery % of dose has been derived from area under the excretion rate (to infinity) from 240h onwards |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax - Maximum Concentration | pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29 | BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite |
| Tmax - Time to Attain Maximum Concentration | pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29 | BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite |
Countries
Netherlands
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Opicapone (OPC) 100 mg OPC
OPC: The drug substance of 100 mg OPC was administered as 1 capsule. | 6 |
| Total | 6 |
Baseline characteristics
| Characteristic | Opicapone (OPC) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 6 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 5 / 6 |
| serious Total, serious adverse events | 0 / 6 |
Outcome results
Primary
Cumulative Recovery of [14C]-Radioactivity
AEurine: Cumulative Recovery of \[14C\]-Radioactivity in urine AEfaeces: Cumulative Recovery of \[14C\]-Radioactivity in urine AEair: Cumulative Recovery of \[14C\]-Radioactivity in urine AEtotal: Cumulative Recovery of \[14C\]-Radioactivity in urine Recovery % of dose has been derived from area under the excretion rate (to infinity) from 240h onwards
Time frame: pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Opicapone (OPC) | Cumulative Recovery of [14C]-Radioactivity | AEfaeces | 67.2 Recovery % of dose | Standard Deviation 7.6 |
| Opicapone (OPC) | Cumulative Recovery of [14C]-Radioactivity | AEurine | 12.8 Recovery % of dose | Standard Deviation 1.5 |
| Opicapone (OPC) | Cumulative Recovery of [14C]-Radioactivity | AEair | 15.9 Recovery % of dose | Standard Deviation 4.8 |
| Opicapone (OPC) | Cumulative Recovery of [14C]-Radioactivity | AEtotal | 95.9 Recovery % of dose | Standard Deviation 8.6 |
Secondary
Cmax - Maximum Concentration
BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite
Time frame: pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Opicapone (OPC) | Cmax - Maximum Concentration | 14C plasma | 7302 ng [eq]/mL | Standard Deviation 3918 |
| Opicapone (OPC) | Cmax - Maximum Concentration | 14C blood | 1920 ng [eq]/mL | Standard Deviation 813 |
| Opicapone (OPC) | Cmax - Maximum Concentration | OPC plasma | 757 ng [eq]/mL | Standard Deviation 321 |
| Opicapone (OPC) | Cmax - Maximum Concentration | BIA 9-1103 plasma | 118 ng [eq]/mL | Standard Deviation 60.9 |
Secondary
Tmax - Time to Attain Maximum Concentration
BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite
Time frame: pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Opicapone (OPC) | Tmax - Time to Attain Maximum Concentration | 14C plasma | 0.51 hours | Standard Deviation 0.01 |
| Opicapone (OPC) | Tmax - Time to Attain Maximum Concentration | 14C blood | 1.01 hours | Standard Deviation 0.01 |
| Opicapone (OPC) | Tmax - Time to Attain Maximum Concentration | OPC plasma | 2.43 hours | Standard Deviation 1.1 |
| Opicapone (OPC) | Tmax - Time to Attain Maximum Concentration | BIA 9-1103 plasma | 8.34 hours | Standard Deviation 3.88 |